Lung cancer patients with tumors harboring a p53 mutation, which accounts for about 50% of all lung cancer cases, were responsive to statin therapy, with higher levels of cancer cell apoptosis, inhibited cell proliferation and more tightly controlled lipid raft regulation [145]. Here, TP53 is linked to lung carcinoma.